Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)
Taiwan · Delayed Price · Currency is TWD 20.60
+0.30 (1.48%)
Sep 15, 2026, 1:56 PM CST
TPEX:6704 Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 157.86 | 187.02 | 170.03 | 141.18 | 180.67 | 242.75 |
Revenue Growth | -15.59% | 10.00% | 20.44% | -21.86% | -25.57% | 28.75% |
Gross Profit Gross Profit Growth | 112.48 | 131.97 | 116.64 | 96.77 | 154.81 | 197.07 |
Operating Income Operating Income Growth | -92.15 | -73.67 | -75.93 | -93.96 | -115.29 | -99.42 |
Net Income Net Income Growth | -99.04 | -80.52 | -83.32 | -88.09 | -112.11 | -106.93 |
Earnings Per Share EPS Growth | -1.04 | -0.84 | -0.87 | -0.98 | -1.31 | -1.29 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Health product income Health product income Growth | 61.75 | 70.25 | 73.76 | 62.84 | 124.25 | 210.76 |
Cell services income Cell services income Growth | 39.97 | 44.98 | 41.97 | 50.83 | 48.03 | 28.71 |
Revenue From Cell Foundry Revenue From Cell Foundry Growth | 32.04 | 44.29 | 33.11 | - | - | - |
Income from inspection of cell quality Income from inspection of cell quality Growth | 24.09 | 27.52 | 21.19 | 27.51 | - | - |
Total Total Growth | 157.86 | 187.02 | 170.03 | 141.18 | 180.67 | 242.75 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 361.74 | 202.53 | 282.79 | 402.47 | 140.97 | 118.62 |
Total Debt Total Debt Growth | 353.2 | 365.27 | 364.46 | 417.02 | 499.07 | 542.44 |
Net Cash (Debt) Net Cash Growth | 8.55 | -162.74 | -81.68 | -14.55 | -358.1 | -423.82 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.09 | -1.70 | -0.85 | -0.16 | -4.19 | -5.11 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -45.21 | -27.98 | -52.28 | -4.87 | -64.19 | -29.12 |
Capital Expenditures CapEx Growth | -24.16 | -52.74 | -23.01 | -12.91 | -17.69 | -43.22 |
Free Cash Flow Free Cash Flow Growth | -69.37 | -80.72 | -75.3 | -17.79 | -81.88 | -72.34 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 71.25% | 70.56% | 68.60% | 68.55% | 85.69% | 81.18% |
Operating Margin | -58.37% | -39.39% | -44.66% | -66.55% | -63.81% | -40.96% |
Pretax Margin | -62.73% | -43.05% | -49.00% | -61.73% | -61.40% | -39.93% |
Profit Margin | -62.74% | -43.05% | -49.00% | -62.40% | -62.05% | -44.05% |
FCF Margin | -43.95% | -43.16% | -44.28% | -12.60% | -45.32% | -29.80% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 12.34 | 13.85 | 15.60 | 24.67 | - | - |